Aligos Therapeutics announces collaboration with Xiamen Amoytop Biotech

Aligos Therapeutics announced that it has entered into a clinical trial collaboration agreement with Xiamen Amoytop Biotech. Under the terms of the agreement, Amoytop will sponsor and perform a Phase 1b exploratory clinical study evaluating the efficacy and safety of ALG-000184 in combination with PEGBING in chronic hepatitis B patients in China. The clinical study is expected to begin after approval by the National Medical Products Administration in China. “We are pleased to build on our existing relationship with Amoytop, as they have proven to be a valuable partner,” stated Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics. “We look forward to initiating this exploratory study to evaluate the combination of ALG-000184 with PEGBING, one of the approved drugs for CHB patients in China, to assess the potential benefits of a combinatory approach.”